-
Kansas City Fed Chief Says Inflation Is Still Running Too Hot
-
Oil Heads for Second Weekly Loss as Supply Surplus Emerges
-
Luxury Skincare Brand Faces Backlash Over Futurist Manifesto Aesthetic
-
Asian Markets Slide as AI Concerns Hit Chip Stocks
-
Brazil Faces Debt and Inflation Test as Lula Prepares Fourth Term
-
Canada Signals Openness to Chinese Automakers if US Trade Talks Fail
-
Canada Expands Asian Trade Push as US Negotiations Resume
-
US Mortgage Rate Falls for Fourth Week but Remains Above 7%
-
US Jobless Claims Rise to 200,000 but Layoffs Remain Historically Low
-
Italy Raises 2026 Growth View but Warns Energy Will Keep Inflation High
-
Godzilla Minus Zero Review: Takashi Yamazaki’s Anti-Nuclear Allegory
-
Euro-Area Growth Slows to 0.4% While Employment Stalls
-
DA Demands No-Work-No-Pay for Striking Municipal Workers in Coalition Talks
-
UK Economy Grows 0.7% in Third Quarter as Services Lead Expansion
-
US Wholesale Inflation Eases Monthly but Hits a Four-Year Annual High
-
India's Retail Inflation Reaches 6.09% as Food Prices Accelerate
-
India's Wholesale Inflation Jumps to 12.29% as Fuel Costs Surge
-
Malta Emerges as Premier Low-Season Destination for UK Travelers
-
China's October Activity Data Reveal a Weak Start to the Fourth Quarter
-
Japan's Economy Edges Into Contraction as Costly Oil Weighs on Demand
-
Philippines Urges ASEAN and China to Accelerate South China Sea Code of Conduct
-
UK Home Asking Prices Drop £6,745 in November Amid High Mortgage Rates
-
Mbeki Claims No Progress Since 2018; Author Cites Infrastructure and Economic Gains
-
Alex Georgiev Sets Personal Record to Win NCAA Pole Vault at Penn Relays
-
Qatar's Amir and Venezuelan Acting President Discuss Energy Cooperation
-
NuRAN Wireless Eliminates Floating-Price Preferred Overhang and Locks In a Fixed C$1.20 Conversion Price
-
SMX: The Future of Gold Will Be Defined by What We Know About It -Powering Verified Trade and Tokenisation
-
Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results
-
Cardiff Lexington Announces Third Quarter 2026 Financial Results
-
Expecting a Refund but Owe Back Taxes? Clear Start Tax Explains How the IRS Offset Program Takes It First
-
MicroVision Lidar Powers Commercial Driverless Trucking at Scale with Kodiak AI
-
Rescue Intellitech Expands Professional Decontamination Portfolio for Fire Departments with DeconWasher(TM) Pro S
-
Westell Technologies, Inc. Announces Its Commencing a Tender Offer
-
SMX Brings a New Level of Transparency to Gold Trading Through trueGold Technology
-
Ainos Reports Third Quarter 2026 Results and Highlights Expanding AI Nose Commercial Momentum
-
Wi2Wi Reports 35% Revenue Growth to US$2.36M and Returns to Profitability with US$268K Net Income in Q3 2026
-
Sharecare Partners With HomeTown Health to Bring AskMD, Funded Through the GREAT Health Program, to More Rural Hospitals and Patients Across Georgia
-
Gladstone Capital Corporation Earnings Call and Webcast Information
-
Medical Care Technologies Inc. (OTCID:MDCE) Follows Q3 Profit Surge With Confirmed Software Development and Expanding Subsidiary Activity
-
GameSquare Holdings Reports 2026 Third Quarter Results with Revenue up 77% YoY and Net Income Reaches $10.1 Million
-
ValorPay UAB Goes Live on T2, the Eurosystem's Real-Time Settlement System
-
CNS Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress in Establishing Transformative Therapeutic Pipeline
-
XCF Global Reports Third Quarter 2026 Financial Results & Affirms 2027 Outlook
-
NextSource Materials Appoints Eugene Lee as Chief Financial Officer
-
International Battery Metals Ltd. Reports Second Quarter of Fiscal Year 2027 Financial Results
-
Abasca Resources Engages Northern Arc Public Affairs to Advance Federal Engagement on the Loki Flake Graphite Project
-
AsiaFIN Holdings Corp. Announces Third Quarter 2026 Results, Reporting Strong Nine-Month Financial Performance with Improved Margins
-
Thalia Therapeutics PLC Announces Promising Interim Phase I Data for miRisten in AML
-
Strategic Metals Reports Promising Results From the Rusty and Ranch Projects
-
Golden Minerals Reports Third Quarter 2026 Financial Results
DEA's Thomas Prevoznik Fails Again: Cannabis Users Poisoned While Pharmaceutical Cannabis Remains Blocked
While the DEA's Thomas Prevoznik Turned a Blind Eye, American Cannabis Users Were Poisoned: How the DEA Regulatory Failure and Inaction Enabled a Public Health Crisis.
WASHINGTON, D.C. / ACCESS Newswire / July 4, 2025 / The Drug Enforcement Administration (DEA) is asleep at the wheel - or worse, willfully negligent - as contaminated cannabis floods state markets, consumers are poisoned, and legitimate pharmaceutical research is actively blocked by the very agency tasked with protecting public health.

At the center of this national disgrace is DEA's Deputy Administrator Thomas Prevoznik, the long-time bureaucrat at the helm of the DEA's Diversion Control Division. While Prevoznik parades around on taxpayer-funded panels pretending to safeguard public safety, the truth is undeniable: the DEA has utterly failed its mission. As stated on the DEA website:
"The mission of DEA's Diversion Control Division is to prevent, detect, and investigate the diversion of controlled pharmaceuticals and listed chemicals from legitimate sources while ensuring an adequate and uninterrupted supply for legitimate medical, commercial, and scientific needs".
State Cannabis Chaos Exposes DEA Incompetence
The latest scandal comes out of Massachusetts, where state regulators just suspended the license of Assured Testing Laboratories -one of the largest cannabis labs in the state-after uncovering what they describe as an "intentional effort to conceal" failing safety results on cannabis products.
The lab, which tested 25% of all cannabis in the state, was caught falsifying reports, hiding contamination, and greenlighting dangerous products that should have failed mandatory yeast, mold, and microbial standards. Thousands of cannabis products were put into consumer hands without accurate safety testing.
Yet not a word from the DEA.
Not a single enforcement action.
No national recall.
No intervention.
The DEA's Mission: Betrayed from Within
The DEA's own mission is crystal clear:
"To prevent, detect, and investigate the diversion of controlled substances while ensuring an adequate and uninterrupted supply for legitimate medical, commercial, and scientific needs."
Under Prevoznik's failed leadership, that mission has become a farce.
The DEA has allowed state cannabis markets to operate as the Wild West: no national oversight, no quality control, no consistency.
Consumers across the U.S. are being exposed to tainted, contaminated cannabis products, while the DEA turns a blind eye.
At the same time, the DEA is actively blocking federally compliant pharmaceutical cannabis development including MMJ BioPharma's FDA-approved clinical research for devastating conditions like Huntington's Disease and Multiple Sclerosis.
Why Is Prevoznik Blocking Science While Allowing Poison?
The hypocrisy is staggering:
The DEA refuses to grant a federal manufacturing license to MMJ BioPharma, whose plant-derived, pharmaceutical-grade cannabis medicines are produced under strict FDA standards.
Meanwhile, Prevoznik's division permits contaminated street level cannabis to flood state markets with no uniform standards, no federal action, and no public warning.
It's the worst of both worlds:
The public is unprotected and medical innovation is obstructed.
The Human Cost of Prevoznik's Failures
Families with children suffering from intractable epilepsy, cancer, or neurological disorders are denied access to standardized, pharmaceutical cannabis because the DEA won't act.
At the same time, recreational markets pump out high-potency THC products riddled with mold, pesticides, and unregulated contaminants: products that in some cases are making people sick.
This is not regulation.
This is dereliction of duty.
Time for Accountability: Fire Prevoznik, Reform DEA
The solution is clear:
Thomas Prevoznik must be immediately removed from his position for gross negligence and regulatory malpractice.
The DEA's obstruction of pharmaceutical cannabis research must end.
Oversight of cannabis research should be transferred to agencies that understand science-such as the FDA or NIH.
Congress must investigate how the DEA has allowed the national cannabis market to devolve into chaos while blocking life-saving medicines from reaching patients.
"The DEA's Diversion Control Division, under Prevoznik's leadership, has failed to protect the public, failed to uphold science, and failed to meet even the most basic standards of competence," said Duane Boise, CEO of MMJ BioPharma Cultivation .
"It's time for the DEA to be held accountable for decades of failure."
The American People Deserve Better
The DEA exists to serve and protect the public, not to act as a political roadblock while Americans are poisoned and scientific progress is stalled.
Prevoznik failed. The DEA failed.
It's time for Congress, the courts, and the public to take back control.
MMJ is represented by attorney Megan Sheehan.
CONTACT:
Madison Hisey
[email protected]
203-231-8583
SOURCE: MMJ International Holdings
View the original press release on ACCESS Newswire
L.Adams--AT